COVID-19 TEDAVİSİNİN NADİR YAN ETKİSİ: FEMUR BAŞI AVASKÜLER NEKROZU
Abstract
Keywords
References
- 1. Alwan NA, Johnson L. Defining long COVID: Going back to the start. Med (New York, N.Y.). 2021;2(5):501-4. https://doi.org/10.1016/j.medj.2021.03.003.
- 2. Assouline-Dayan Y, Chang C, Greenspan A, et al. Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum. 2002;32(2):94-124. https://doi.org/10.1053/sarh.2002.33724b
- 3. Campbell C, Andersson MI, Ansari MA, et al. Risk of reactivation of hepatitis B virus (HBV) and tuberculosis (TB) and complications of hepatitis C virus (HCV) following tocilizumab therapy: a systematic review to inform risk assessment in the COVID-19 era. Front Med. 2021;8:706482. https://doi.org/10.3389/fmed.2021.706482.
- 4. Fye MA, Huo MH, Zatorski LE, et al. Total hip arthroplasty performed without cement in patients with femoral head osteonecrosis who are less than 50 years old. J Arthroplasty. 1998;13(8):876-81. https://doi.org/10.1016/s0883-5403(98)90193-0.
- 5. Hoenigl M, Seidel D, Sprute R, et al. COVID-19-associated fungal infections. Nat Microbiol. 2022;7(8):1127-40. https://doi.org/10.1038/s41564-022-01172-2
- 6. Huscher D, Thiele K, Gromnica-Ihle E, et al. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis. 2009;68(7):1119-24. https://doi.org/10.1136/ard.2008.092163
- 7. Marconi VC, Ramanan AV, de Bono S, et al. COV-BARRIER Study Group. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet. 2021;9(12):1407-18. https://doi.org/10.1016/S2213-2600(21)00331-3
- 8. Mavi D, İnkaya AÇ. COVID-19 İmmün patogenez. FLORA. 2020;25 https://doi.org/ 10.5578/flora.69606
Details
Primary Language
Turkish
Subjects
Clinical Sciences, Medical Microbiology
Journal Section
Case Report
Authors
Arda Kaya
*
This is me
0000-0003-3491-5412
Türkiye
Hüseyin Aytaç Erdem
This is me
0000-0001-7375-977X
Türkiye
Dündar Sabah
This is me
0000-0002-3391-2597
Türkiye
Tansu Yamazhan
0000-0001-5950-0702
Türkiye
Meltem Taşbakan
0000-0002-4689-720X
Türkiye
Publication Date
April 28, 2023
Submission Date
October 31, 2022
Acceptance Date
March 27, 2023
Published in Issue
Year 2023 Volume: 37 Number: 1
